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Abstract
Background and objectives Cancer poses a substantial health and economic burden on patients and caregivers in Canada. 
Previous reviews have estimated the indirect cost burden as work-related productivity losses associated with cancer. How-
ever, these estimates require updating and complementing with more comprehensive data that include relevant dimensions 
beyond labor market costs, such as patient time, lost leisure time and home productivity losses.
Methods A systematic review of the literature was conducted to identify studies published from 2006 to 2020 that meas-
ured and reported the indirect costs borne by cancer patients and their caregivers in Canada, from the patient, caregiver, 
employer, and societal perspectives. Study characteristics and cost estimation methods were extracted from relevant studies. 
Costs estimates were reported and converted to 2020 CAD for the following categories: lost earnings, caregiving time costs, 
home production losses, patient time (leisure), morbidity-, disability-, premature mortality-related costs, friction costs, and 
overall productivity losses. A quality assessment of individual studies was conducted for included studies using the New-
castle–Ottawa Assessment Tool.
Results In total, 3980 studies were identified, of which 18 Canadian studies met the inclusion criteria for review. One-third 
of the studies used or developed prediction models, 38% enrolled patient cohorts, and 27% used administrative databases. 
Over one-third of the studies were conducted at a national level (38%). All studies employed the human capital approach to 
estimate costs, and 16% also used the friction cost approach. Lost earnings were higher among self-employed patients (43% 
vs 24% among employees) and females ($8200 vs $3200 for males). Caregiver costs ranged from $15,786 to $20,414 per 
patient per year. Household productivity losses were estimated to be up to $238,904 per household per year. Patient time 
(leisure) costs were estimated to be between $13,000 and $18,704 per patient per year. Premature annual mortality costs 
were estimated to be $2.98 billion overall in Quebec. Friction costs incurred by employers were estimated between $6400 
and $23,987 per patient per year. Societal productivity losses associated with cancer were estimated between $75 million 
to $317 million, annually.
Conclusions This review suggests that the indirect cost burden of cancer is considerable from the patient, caregiver, employer, 
and societal perspectives. This up-to-date review of the literature provides a comprehensive understanding of the indirect 
cost burden by including non-labor market activity costs and by examining all relevant perspectives. These results provide 
a strong case for the government and employers to ensure there are supports in place to help patients and caregivers buffer 
the impact of cancer so they can continue to engage in productive activities and enjoy leisure time.
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Key Points for Decision Makers 
Cancer patients, their caregivers, and employers bear a 
considerable indirect cost burden related to cancer care 
in Canada.
The indirect cost burden of cancer is not limited to the 
productive labor market costs incurred by patients. 
Patient leisure time and home-production losses are 
important cost categories that must be considered when 
measuring the indirect cost burden.
The caregivers of pediatric patients, women, younger 
patients, and those who were self-employed face higher 
indirect costs in Canada.
1 Introduction
Cancer is a common chronic disease that has a large impact 
globally, including in Canada. Around half of the popula-
tion is expected to develop cancer in their lifetime [1], and 
it remains the leading cause of premature mortality [2]. Fur-
thermore, cancer poses a substantial health and economic 
burden on patients, their caregivers, and the healthcare sys-
tem, given its high incidence (over 200,000 cases per year 
in 2019), long-term health effects, and rising treatment costs 
[3].
The economic burden is typically conceptualized as three 
distinct categories: direct, indirect, and psychosocial [4]. 
Cost of illness studies are often conducted to estimate the 
direct and indirect costs associated with a given disease; in 
turn, these estimates are used to support cost-effectiveness 
analyses, which are critical for informing resource alloca-
tion decisions [5]. Although the direct burden of cancer in 
Canada has been previously described [6], evidence around 
the indirect costs associated with cancer care is sparse and 
limited. The indirect burden includes the monetary losses 
associated with lost patient/caregiver time and lost opportu-
nities due to disease morbidity and related premature mortal-
ity (also defined as opportunity costs) [7]. These costs are 
incurred by patients, caregivers, employers, and society as 
a whole; however, because lost opportunities are usually not 
reflected in monetary transactions, the value of the time lost 
must be approximated. Thus, to obtain an overall estimate of 
the indirect cost burden, the time that cancer patients spend 
in obtaining treatment, loss from not working due to short- 
or long-term cancer-related disability, and the lost productiv-
ity due to premature death are monetized and combined [7].
In a report conducted by the Public Health Agency of 
Canada, work-related productivity losses due to cancer were 
estimated to be $586,000,000 in 2008 [8]. Subsequently, a 
review conducted in 2010 identified studies published before 
2008 that had estimated wage losses due to cancer [9] and 
found that newly diagnosed cancers in Canada generated an 
average wage loss of $3.18 billion per year. However, these 
studies only included labor market-related production losses. 
Considering the lack of up-to date and comprehensive esti-
mates, and the fast pace at which cancer care has evolved 
in the last decade [10], the evidence around the indirect 
cost burden of cancer in Canada needs to be re-evaluated 
to include recent studies that also capture non-labor market 
activities, such as home production, leisure, and caregiving 
time. Therefore, the aim of this review was to evaluate the 
most recent Canadian literature on the indirect cost burden 
associated with cancer from the perspectives of patients, 
families, caregivers, employers, and society.
2  Methods
2.1  Data Sources and Search Strategies
A systematic review of the literature was conducted to iden-
tify studies that estimated and/or reported on the indirect 
cost burden of cancer in Canada. We searched MEDLINE, 
EMBASE (Excerpta Medical Database), CINAHL, Econlit, 
PsychINFO, Cochrane, and Erudit (this last to capture lit-
erature published in French). We also searched Open Gray 
to account for relevant gray literature. All databases were 
searched between January 1, 2006 and January 8, 2020. 
Search terms combined medical subject headings (MeSH), 
Embase subject headings (Emtree), and keywords for cancer 
(e.g. oncology), economic burden (e.g. costs), and indirect 
costs (e.g. productivity loss). In addition, we searched the 
reference lists of all included studies to identify additional 
relevant studies. The full search strategy and key words 
can be found in Appendix 1. We followed the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines [11] as presented in Appendix 2.
2.2  Eligibility Criteria
We included any study that reported and/or estimated the 
indirect cost burden of cancer patients and/or their caregiv-
ers. No study design or language restrictions were applied 
to the search. Studies were excluded if at least one of the 
following criteria was met: studies evaluated non-cancer 
populations, only reported or measured costs that were not 
defined as indirect costs (e.g. out-of-pocket), were not full-
text articles (e.g. conference abstracts), or were conducted 
without employing Canadian data. After running the search, 
The Indirect Cost Burden of Cancer Care in Canada
the identified records were screened by title and abstract, 
followed by a full-text review by two independent reviewers 
(NI and BE). Any article that either reviewer included at the 
title/abstract review stage was included for full-text review. 
Disagreements at the full-text stage were settled by discus-
sion until a consensus was reached with a third reviewer 
(CdO).
2.3  Data Extraction
We extracted the following data from the included studies: 
authors’ names, title of the study, year of publication, type 
of publication (e.g. article, report), jurisdiction (e.g. federal-, 
province- or territory-level analysis), cancer site, cancer care 
continuum (from diagnosis to end-of-life care), study popu-
lation, type of study (e.g. prospective), sample size, mean 
age of population examined, proportion of females reported 
in the study, employment status, income level, control/com-
parison group, and databases/sources used. Regarding the 
outcome of interest, we extracted data on the definition of 
the indirect cost, methods, and tools (e.g. surveys) used to 
measure the indirect costs, cost estimates, currency, currency 
year, and time frame or recall period. Costs were reported 
and divided by different categories: (1) lost earnings (at the 
patient level), (2) caregiving time costs; (3) home production 
losses, defined as production activities within the household, 
which are usually not remunerated (e.g. cleaning). Caregiv-
ing costs and home production losses were reported sepa-
rately, as caregiving might not always be delivered at home; 
(4) lost patient time (i.e. lost leisure time) (5) morbidity-, 
disability-, and premature mortality-related costs (produc-
tivity losses and time lost due to cancer-related disability 
and mortality); (6) friction costs (costs that employers incur 
when replacing absentees); and (7) aggregated productivity 
losses from a societal perspective.
2.4  Quality Assessment
Quality assessment was ascertained using the Newcastle-
Ottawa Assessment Tool [12] and conducted by two inde-
pendent reviewers (NI and BE). Prospective and retrospec-
tive studies were evaluated with specific versions adapted to 
cohort and cross-sectional study designs, respectively [12]. 
Three domains were evaluated for all prospective and ret-
rospective studies: selection (i.e. representativeness of the 
sample), comparability (i.e. comparability of subjects, inclu-
sion of confounding factors), and outcome (i.e. assessment 
of outcome, statistical test used). A ‘star system’ was used 
to judge the extent to which each individual study accounted 
for issues concerning these three categories. Each domain 
was assessed for risk of bias (unclear, low, or high) accord-
ing to the total score assigned and the pre-specified and 
validated thresholds identified by the tool developers. For 
retrospective studies, the maximum scores for the Selection, 
Comparability and Outcome domains were 5, 2, and 3 stars, 
respectively. Studies were identified as having low risk of 
bias if their overall score was 8 or higher. Studies with an 
overall score below 5 were identified as having a high risk 
of bias. For prospective studies, the maximum scores for the 
Selection, Comparability and Outcome domains were 4, 2, 
and 3 stars, respectively. Studies were identified as having 
low risk of bias if the Selection, Comparability, and Out-
come domains scored at least 3, 1, and 1 star(s), respectively. 
Studies were identified as having high risk of bias if the 
Selection domain scored less than 2 stars, or if the Com-
parability or Outcomes domains scored no stars. Quality 
assessment was not conducted for studies that used predic-
tive models based on incidence cost approaches.
2.5  Evidence Synthesis
We provided a description of the different types of costs 
reported in the literature and conducted a narrative syn-
thesis of the estimation methods employed. Indirect costs 
were reported as an annual expenditure, and converted to 
2020 Canadian dollars (CAD) using the Consumer Price 
Index from the Bank of Canada Inflation Calculator [13]. A 
meta-analysis was not undertaken due to the heterogeneity 
of the patient populations and cost definitions. Therefore, we 
undertook a narrative synthesis of the literature.
3  Results
3.1  Summary of Studies
Searches on the electronic database identified 3980 records, 
of which 3009 were unique (971 duplicates); 403 were 
included for full-text review. Among the 403 studies, 18 
Canadian studies were ultimately retained [14–31]. The 
results of the electronic searches, the eligibility criteria and 
the reasons for exclusion are presented in Fig. 1. Over half 
of the excluded records (62%) in the title/abstract review 
stage reported costs that were not relevant (e.g. direct costs), 
and 18% of the full-text studies failed to explicitly report 
or measure indirect costs. Non-Canadian studies were only 
excluded during the full-text review (n = 151).
The study characteristics of the included studies are 
summarized in Table 1. The combined sample size of the 
18 studies was 550,501 cancer patients and/or caregivers 
and ranged from 50 to 196,050 individuals. Studies with 
large samples usually identified cases through the linkage 
of various administrative datasets, such as the Canadian 
Cancer Registry, census data, the Labour Force Survey, 
the Canadian Community Health Survey, and the tax files. 
A total of 547,162 cancer patients were identified through 
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these databases. Cohort studies were usually smaller due 
to the elevated costs associated with enrolling and follow-
ing patients over time and collecting data on their incurred 
indirect costs; a total of 1962 patients and 1377 caregivers 
were enrolled in the prospective studies. Seven studies were 
prospective (38%), five were retrospective (28%) and 6 used 
mathematical models (33%) to predict cancer cases and esti-
mate the indirect cost burden. The papers with predictive 
models employed Markov chains [19], population attrib-
utable fractions [20, 25], and incidence-based approaches 
using data from cancer registries [14, 21, 26]. The publica-
tion years ranged from 2006 to 2018. Seven studies (38%) 
reported on the indirect cost burden of cancer at the national 
level, while 6 (33%) focused exclusively on Ontario, 3 (17%) 
on Quebec, and 1 (5%) on Nova Scotia. One study (5%) 
evaluated the indirect cost burden on multiple provinces 
(Manitoba, Quebec, and Nova Scotia). Regarding patient 
populations, half evaluated multiple cancer types. Among 
these, two focused exclusively on pediatric populations. The 
remaining studies estimated costs for individual cancer sites, 
including breast, bladder, colorectal, lung, prostate, lung, 
mesothelioma, and melanoma. The mean age of the non-
pediatric populations ranged from 48 to 73 years of age, 
while the mean age for the pediatric populations was 7.8 
years. The percentage of females was close to 50% for most 
studies. Finally, half of the studies evaluated the indirect 
burden across the entire cancer care continuum, from diag-
nosis to palliative and end-of-life care. Three studies (16%) 
focused exclusively on patients undergoing cancer treatment; 
two (11%) on palliative and end-of-life care, and two (11%) 
on survivorship.
3.2  Indirect Costs
The reported indirect costs were extracted and divided into 
the following categories: lost earnings, caregiver time costs, 
home production losses, patient leisure time costs, premature 
death/disability costs, friction costs, and societal productiv-
ity losses:
1. Lost earnings
  The estimates of the indirect costs were reported by 
category and presented in Table 2. Further information 
regarding the cost definitions and methods of estimation 
for each study is summarized in Appendix 3. The most 
commonly reported indirect costs were lost earnings for 
cancer patients and their caregivers. After transforming 
all estimates to annual costs, the average wage loss ranged 
from $4538 (in 2020 CAD) for the members of the fami-
lies’ support networks who resided outside the families’ 






























Table 1  Study characteristics
First author 
and year
Jurisdiction Study population Databases Cancer site Cancer care 
continuum
Sample size Mean age (SD) % of sample 
female









Cancer patients in 
palliative care and 
their caregivers, 
from urban and 
rural settings
Enrolled patients in a 
regional palliative 
care program
Multiple Palliative care Total = 416




80 patients and 
84 caregiv-
ers from rural 
areas




Lauzier et al.  
2010 [22]
Quebec Breast cancer patients 
and their caregivers
Patients enrolled Breast Treatment,  
Survivorship
50 (26 patients 
and 24 caregiv-
ers)




Lauzier et al.  
2008 [23]




Breast Treatment,  
Survivorship
800 50.3 (7.2) 100% 57% 702 (537) weekly
Longo et al.  
2006 [24]
Ontario All outpatient cancer 
clinic patients aged 
> 18 years receiv-
ing treatment for 
breast, colorectal, 
lung, or prostate 
cancer
Patients enrolled Breast, Colo-
rectal, Lung, 
Prostate
Treatment 282 60.6 44% NR 36% earned < 
20,000 per year
Tsimicalis 
et al.  2013 
[28]
Ontario Households with chil-
dren with cancer




Treatment 99 7.8 (5.2) 57% NR NR
Tsimicalis 
et al.  2012 
[29]
Ontario Households with chil-
dren with cancer




Treatment 99 7.8 (5.2) 57% NR NR
Yu et al.  2015 
[31]
Ontario Patients with terminal 
cancer and their 
caregivers




186 patients and 
their caregivers
NR 55% 48% NR
Retrospective studies employing patient records and/or administrative datasets
de Oliveira 
et al.  2014 
[15]

















Table 1  (continued)
First author 
and year
Jurisdiction Study population Databases Cancer site Cancer care 
continuum
Sample size Mean age (SD) % of sample 
female
% of sample 
employed
Mean income
Jeon et al.  
2017 [17]
Canada Cancer patients aged 
< 62 years, who 
survived for at 
least 3 years after 
diagnosis
1991 Census-Longi-
tudinal Worker File 
[LWF), Canadian 
Cancer Data-





Multiple Survivorship 2597 48.12 (NR) 62.80% NR $43,689 per year
Jeon et al.  
2017 [18]
Canada Spouses of cancer 
patients aged < 59 
years
Canadian 1991 Cen-






dinal Worker File 
(LWF), T1 Family 
File (T1FF)
Multiple From cancer 
diagnosis 
onward





Tompa et al.  
2017 [27]
Canada Mesothelioma and 
asbestos-related 













and End Results 
(SEER) registry, 
2010 Canadian Sur-







































Table 1  (continued)
First author 
and year
Jurisdiction Study population Databases Cancer site Cancer care 
continuum
Sample size Mean age (SD) % of sample 
female
% of sample 
employed
Mean income
Wranik et al.  
2017 [30]
Nova Scotia Occupational cancer 
cases from 1996 to 
2013 in Nova Scotia
Workers Compensa-












304 NR NR 100% NR
Predictive models
Boucher et al.  
2010 [14]
Quebec Predicted cancer 
patients in 2008
Institut de la statis-
tique du Quebec 
data on GDP and 
other Quebec 
administrative data, 
Fichier des tumeurs 
du Quebec (1984-
1998)





NR 52% NR NR
Jung et al.  
2018 [19]
Canada Occupational bladder 
cancer patients







2010 Survey of 









NR NR NR NR
Krueger et al.  
2016 [20]
Canada Model-based attribut-















NR NR NR NR
Krueger et al.  
2010 [21]





Melanoma From cancer 
diagnosis 
onward
4775 cases in 
2004






Table 1  (continued)
First author 
and year
Jurisdiction Study population Databases Cancer site Cancer care 
continuum
Sample size Mean age (SD) % of sample 
female
% of sample 
employed
Mean income
Mofidi et al.  
2018 [25]
Canada Model-based attribut-














dian Labour Force 














NR NR 100% NR
Smetanin 
et al.  2011 
[26]
Ontario Lung cancer cases in 
2011 and predic-
tions for 2041
Cancer Care Ontario 
(CCO), CCR data-
base, CANSIM




cases on lung 
cancer in 
2011 - 11,568 
predicted cases 
in 2041
68 (NR) 48% NR NR






























Table 2  Reported indirect costs by category
Cost category Author Original cost estimate Cost per year in 2020 CAD Unit Province Cancer type
Lost earnings (patients) Jeon et al.  2017 [17] Lost earnings unconditional 
on working = $4832 per year 
(9.8% reduction compared 
with controls)
$5743 Per patient Canada Multiple
Jeon et al.  2017 [18] Lost earnings for males = 




Per patient Canada Multiple
Jung et al.  2018 [19] Total lost productivity = 
$71,562 per case per year
$83,256 Per patient Canada Bladder (occupational)
Lauzier et al.  2010 [22] Lost earnings among self-
employed patients = 37% 
median wage loss and 18% 
among salaried employees
- - Quebec Breast
Lauzier et al.  2008 [23] Average wage loss of 27% 
($9311) of the projected 
annual salary, after tak-
ing into account financial 
compensation (43% among 
self-employed, and 24% 
among employees)
$12,440 Per patient Quebec Breast
Longo et al.  2006 [24] 20% patients who were work-
ing lost mean income of 
$1270 over 30 days
$101 per day of work missed
$46,900 Per patient Ontario Breast, colorectal, lung, prostate
Tompa et al.  2017 [27] Wage loss for mesothelioma:
$26,501,879 in 2011 ($62,102 
per case)
Wage loss for asbestos-related:
$126,275066 in 2011 $66,314 
per case)
$72,250 (mesothelioma)
$ 77,151 (asbestos-related lung 
cancer)
Per patient Canada Lung, mesothelioma
Tsimicalis et al.  2013 [28] Monetary work loss over 
3-month period:
$910
$4538 Per patient Ontario Pediatric cancer (e.g. leukemia, 
lymphomas)
Yu et al.  2015 [31] Cost of lost time from employ-
ment:
$84.06 over the entire pallia-
tive trajectory






Table 2  (continued)
Cost category Author Original cost estimate Cost per year in 2020 CAD Unit Province Cancer type
Caregiving time costs Boucher et al.  2010 [14] Cost supported by caregiv-
ers was of $177.7 million 
in Quebec in 2008 (cost per 
family = $7468)
$9145 Per household Quebec Multiple
Dumont et al.  2015 [16] Rural areas: $4616 caregiving 
time per 6 months
Urban areas: $4559 caregiving 
time per 6 months
$10,972 (rural areas)
$10,836 (urban areas)




Jung et al.  2018 [19] Informal caregiver costs = 
$17,547 per case per year
$20,414 Per patient Canada Bladder (occupational)
Longo et al.  2006 [24] 35% of family caregivers lost 
$700 per month
- - Ontario Breast, colorectal, lung, prostate
Tompa et al.  2017 [27] Cost for informal care:
Mesothelioma:
$5,790,544 ($13,569 per case)
Asbestos-related:
$32,857,086 ($17,255 per 
case)
$15,786 (mesothelioma)
$20,074 (asbestos-related lung 
cancer)
Per patient Canada Lung, mesothelioma
Tsimicalis et al.  2012 [29] Opportunity cost of providing 
care to child:
$1,259 to 49,236
Mean family opportunity cost: 
$22,873 per 3 months
$1569–$61,388 Per patient Ontario Pediatric cancer (e.g. leukemia, 
lymphomas)
Home production losses Jung et al.  2018 [19] Home production losses - 
$20,864 per case per year
$24,273 Per patient Canada Bladder (occupational)
Mofidi et al.  2018 [25] Basal cell carcinoma: $491,744 
per year ($173 per case)
Squamous cell carcinoma: 
$499,990 per year ($292 per 
case)
$201 (basal cell carcinoma)
$339 (squamous cell carci-
noma)
Per patient Canada Non-melanoma skin cancer 
(occupational)
Tompa et al.  2017 [27] Mesothelioma:
$87,632,043 ($205,347 per 
case)
Asbestos-related:





Per patient Canada Lung, mesothelioma
Yu et al.  2015 [31] Household work-related costs:
$2085.17 over the entire pallia-
tive trajectory






























Table 2  (continued)
Cost category Author Original cost estimate Cost per year in 2020 CAD Unit Province Cancer type
Patient time-leisure costs de Oliveira et al.  2014 [15] Time costs: $838 ($442–1233) 
per year
$1044 Per patient Ontario Prostate
Morbidity, short-term 
disability, and premature 
mortality
Krueger et al.  2010 [21] Non-workforce participation 
costs = $250M (leisure time 
and unpaid work)
$331.8 billion Society Canada Melanoma
Tsimicalis et al.  2013 [28] Monetary leisure time over 
3-month period:
$3751
$18,704 Per patient Ontario Pediatric cancer (e.g. leukemia, 
lymphomas)
Yu et al.  2015 [31] Leisure time-related costs:
$13,728.42 over the entire pal-
liative trajectory
- - Ontario Multiple
Morbidity, short-term 
disability, and premature 
mortality
Boucher et al.  2010 [14] Premature mortality: $2.42 bil-
lion for Quebec in 2008
$ 2.98 billion Society Quebec Multiple
Krueger et al.  2016 [20] Short-term disability among 
females – $51M
Short-term disability among 
males – $66M
Long-term disability among 
females – $282M
Long-term disability among 
males – $369M
$57.1 million – short term 
(females)
$73.9 million – short term 
(males)
$315.7 million - long term 
(females)
$413 million – long term 
(males)
Society Canada Multiple
Krueger et al.  2016 [20] Premature mortality among 
females – $3.1B ($1.3B 
attributable to tobacco)





Krueger et al.  2010 [21] Indirect costs due to premature 
mortality: $457 million for 
2004, $741.96 million for 
2031; morbidity: $8.7 million 
for 2004, $17.98 million for 
2031
$ 606 million (premature 
mortality)
$ 11.5 million (morbidity)
Society Canada Melanoma
Friction costs Boucher et al.  2010 [14] $72.2 million in Quebec in 
2008
$88.4 million Society Quebec Multiple
Jung et al.  2018 [19] $20,618 per case per year $23,987 Per patient Canada Bladder (occupational)
Tompa et al.  2017 [27] Mesothelioma:
$2,360,170 ($5531 per case)
Asbestos-related:
$10,542,816 ($5537 per case)
$6434 (mesothelioma)
$6450 (asbestos-related lung 
cancer)






Table 2  (continued)
Cost category Author Original cost estimate Cost per year in 2020 CAD Unit Province Cancer type
Lost productivity (society) Boucher et al.  2010 [14) $258.9 million for decrease 
in labor participation rate in 
Quebec in 2008
$317 million Society Quebec Multiple
Mofidi et al.  2018 [25] Basal cell carcinoma: $650,515
Squamous cell carcinoma: 
$6988,950
$756,822 (basal cell carci-
noma)
$8,131,090 (squamous cell 
carcinoma)
Society Canada Non-melanoma skin cancer 
(occupational)
Smetanin et al.  2011 [26] Total wage-based productivity 
lost for 2011 = $135.4 M
Total wage-based productivity 
lost for 2041 = $1.1B
$157 million (2004)
$1.8 billion (2041 prediction)
Society Ontario Lung
Tompa et al.  2017 [27] Total productivity losses:
Mesothelioma:
$117,130,994 in 2011 
($276,143 per case)
Asbestos-related:





Society Canada Lung, mesothelioma
Wranik et al.  2017 [30] Total cost from 1996 to 2013 
for Canada:
$1,228,763,000
Average annual cost for 
Canada:
$68,265,000
$75,571,107 Society Nova Scotia Multiple
CAD Canadian Dollars
The Indirect Cost Burden of Cancer Care in Canada
home in Ontario [28] to $83,256 among patients with 
bladder cancer nationwide [19]. The evidence suggests 
that self-employed patients faced higher earning losses 
compared to salaried patients. Two studies conducted in 
Quebec estimated that self-employed patients with breast 
cancer experienced a wage loss of 48% and 37% of their 
projected salary, compared with 24% and 18% among 
salaried patients, respectively [22, 23]. On the other 
hand, a study that used a prediction model to calculate 
the productivity losses of the spouses of cancer patients 
estimated higher annual mean costs among females com-
pared to males ($8201 and $3209, respectively) [18].
2. Caregiver time costs
  Caregiver time costs were reported to account for 
non-labour market-related costs. Six studies reported 
a monetary value associated with the time that people 
spent caring for cancer patients. The average annual cost 
ranged from $15,786 among patients with mesothelioma 
[27] to $20,414 for patients with bladder cancer nation-
wide [19]. One study estimated average caregiver time 
costs, which ranged from $1569 to $61,388 for parents 
caring for a child with cancer in Ontario [29]. Another 
study conducted in Manitoba, Nova Scotia, and Quebec 
estimated that caregivers from rural and urban settings 
faced similar average annual indirect costs related to 
informal care ($10,972 and $10,836, respectively) [16].
3. Home production losses
  Home production losses are a different type of non-
market activity costs, which pertain to production activi-
ties within the household, such as cooking and childcare, 
and that do not usually involve a monetary transaction. 
Home production losses were estimated using an aver-
age hourly wage for housekeepers and related occupa-
tions. Therefore, home production was often measured 
as zero for terminal cases due to the inability to work 
at home. Four studies reported home production losses, 
with annual average estimates ranging from $201 for 
patients with basal cell carcinoma (skin cancer) [25] 
to $238,904 among patients with mesothelioma [27]. 
Average household productivity costs were estimated at 
around $2500 per patient per year in Ontario [31].
4. Patient leisure time costs
  Patient leisure time costs were estimated in four stud-
ies (three conducted in Ontario and one at the national 
level) by determining the total personal/leisure time lost 
by patients and their caregivers due to cancer. As an 
example, de Oliveira et al.  (2016) defined these costs 
as the time taken by patients and an accompanying per-
son to visit health professionals as well as lost leisure 
time [15]. This time spent seeking care is considered an 
opportunity cost, as it could have been used to work or 
spent on different productive or non-productive activi-
ties (e.g. leisure). Although these estimates are not nec-
essarily related to the labour market, all were estimated 
using an average hourly wage to assign a monetary value 
to the time lost. Krueger et al.  estimated total nation-
wide costs related to lost leisure time and unpaid work as 
a result of cancer to be around $331 billion per year [21]. 
Tsimicalis et al.  estimated lost leisure time of $18,704 
per year per parent who cared for children with cancer 
in Ontario [28]; Yu et al.  estimated a similar cost of 
$13,000 per year per cancer patient [31].
5. Premature death/disability costs
  Premature mortality and disability-related costs are 
specific types of productivity losses, which are associated 
with a loss of earnings/time due to the disease. Cancer 
patients who cannot go back to work (in the labor market 
or in the household) due to disease-related disabilities 
incur additional indirect costs. Patients who eventually 
die of cancer face similar costs due to premature mortal-
ity. Therefore, younger patients usually incurred higher 
premature mortality costs due to overall productivity 
losses [20]. Four studies estimated these costs. Two stud-
ies concluded that males faced higher average short- and 
long-term disability-related costs relative to females ($66 
million vs $51 million, and $369 million vs 282 million, 
respectively) [20]. A study in Quebec estimated an annual 
indirect cost associated with cancer-related mortality at 
around $2.98 billion [14]. Another study estimated an 
annual cost of $606 million due to premature mortality, 
and $11.5 million due to morbidity caused by melanoma 
at a national level [21]. Finally, the indirect cost associ-
ated with premature cancer-related mortality attributable 
to tobacco was estimated at $2.4 billion for males and 
$1.7 billion for females at the national level [20].
6. Friction costs
  Friction costs were estimated in three studies. The 
friction cost approach defined friction costs as the costs 
and time that employers incur to replace workers who 
become absent due to cancer and to train the new work-
ers who replace them [32]. In Quebec, the total friction 
cost faced by employers was estimated to be about $88.4 
million per year [14]. This cost accounted for the chain 
effect of job vacancies and friction time that occur as 
people shift between positions as they become available. 
Other studies found an annual friction cost of $23,987 
per patient among a bladder cancer population [19], and 
$6400 per patient with lung cancer [27].
7. Societal productivity losses
  Finally, five studies estimated productivity losses at 
the societal level. Unlike the previous categories, these 
estimates accounted for different types of indirect costs, 
such as lost productivity and home productivity losses 
in a single value. The overall productivity loss to society 
represents a multidimensional and more comprehensive 
measure of the indirect cost. The annual productivity 
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loss due to a decrease in labor market participation 
associated with cancer was estimated at $317 million in 
Quebec [14]. The same cost was estimated to be around 
$157 million in Ontario among lung cancer patients 
[26]. Lastly, Wranik et al.  estimated total productivity 
losses in Canada due to cancer from 1993 to 2013 and 
found an average cost of $75 million per year [30].
3.3  Approaches to Measuring Indirect Costs
Productive labor market costs: All studies, which estimated 
work productive labor market costs, employed the human 
capital approach [33]. To obtain total and per-patient indirect 
cost estimates, some studies used a setting-specific average 
wage to assign a monetary value to the time lost from work 
and multiplied it by the overall time lost attributed to cancer. 
Other studies estimated patient-level costs based on the indi-
vidual reported wages from tax files, surveys, or interviews. 
Three studies also employed the friction cost approach to 
estimate the short-term costs that employers incur due to 
absenteeism (staying home while sick) of cancer patients 
and their caregivers [14, 19, 27]. These costs pertain to the 
time required by employers to recruit and train new workers.
Productive non-labor market costs: These costs pertain 
exclusively to activities that are not related to labor market 
activities. Studies that reported on these costs also used the 
human capital approach to assign a monetary value to the 
leisure time lost, the time spent caring for patients, home 
production losses, and unpaid work.
3.4  Quality Assessment
The risk of bias assessment of retrospective and prospective 
studies is presented in Figure 2 and Appendix 4. While more 
than half of the studies had a low risk of bias, the studies with 
unclear and high-risk of bias usually failed to provide a thor-
ough description of patient recruitment or the tools utilized to 
measure and report the outcome of interest. Overall, 60% of 
the retrospective studies had a low risk of bias, mainly due to 
a selection of an adequate and representative sample. Most of 
these studies employed administrative databases that allowed 
the identification of large samples that are usually generaliz-
able. Furthermore, some of these studies with low risk of bias 
defined a control group of non-cancer patients to estimate 
incremental costs rather than net costs. They also employed 
various regression and statistical analyses that allowed con-
trolling for potential confounder variables to further explain 
how different factors might be associated with indirect costs. 
However, 40% of the studies failed to provide a detailed and 
adequate methodology to select a representative sample size. 
Since the comparability and outcome dimensions were com-
plete and appropriately defined, these studies were identified 
as having unclear risk of bias. No cross-sectional study had a 
high risk of bias. A similar proportion of prospective cohort 
studies had a low risk of bias (57%). These studies adequately 
ensured that most patients were adequately followed-up and 
that the outcome assessment of the indirect cost burden had 
well-defined time horizons. Studies with unclear (29%) and 
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Fig. 2  Quality assessment of individual studies using the Newcastle-Ottawa Assessment Tool
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recruitment process to ensure representativeness of the sample 
or lacked a thorough description of how the outcomes were 
assessed (i.e. self-reports).
4  Discussion
This study presents an up-to-date and comprehensive review 
of the most recent literature on the indirect cost burden of 
cancer in Canada. We systematically reviewed studies that 
estimated labor and non-labor market-related costs, ranging 
from lost earnings to household productivity losses. The evi-
dence suggests that cancer patients and their caregivers face 
a substantial indirect cost burden due to premature mortality 
and short- and long-term disabilities. Most of the reported 
costs were work-related productivity losses, rising to $80,000 
per patient per year. Leisure time costs and home produc-
tion losses were also considerable, with maximum estimates 
of $18,000 and $240,000 per patient per year, respectively. 
Friction costs borne by employers were estimated at around 
$24,000 per patient per year. Annual productivity losses at 
the societal level ranged from $75 million in Nova Scotia to 
$317 million in Quebec. We also found that caregivers of 
pediatric patients, women, younger patients, and those who 
were self-employed tended to face higher indirect costs.
A previous report by the Public Health Agency of Canada 
(PHAC) used a prevalence-based approach to evaluate the 
economic burden of chronic conditions between 2005 and 
2008, and estimated the indirect cost of cancer to be around 
$586,000,000 in 2008 [8]. However, this value was likely 
underestimated, since the definition of the indirect cost bur-
den was limited to the production losses due to illness, injury 
or premature death [8]. Other costs associated with non-
labor market activities, such as leisure time and informal 
caregiving, were not considered. Similarly, Hopkins et al. 
conducted a multi-database literature search on the national 
wage loss from cancer in Canada [9]. The studies identi-
fied in this review also limited their analyses to work-related 
costs. Our results provide an up-to-date and complete review 
of the indirect cost burden of cancer in Canada, by including 
literature published within the last 15 years and non-market-
related costs, which account for a considerable portion of the 
burden. This review highlights the importance of ensuring 
that future reports and reviews reflect a more comprehensive 
assessment of the indirect burden of cancer to better account 
for all of the dimensions identified in this study in Canada
Two methods were identified in the literature to meas-
ure indirect costs – the human capital and the friction cost 
approaches. The human capital methodology applies average 
wages by sex and age to estimate the value of the time lost, 
usually from a labor market perspective [33]. Even though 
some indirect costs are not explicitly linked with workplace 
productivity (e.g. leisure time, or home productivity losses), 
the human capital estimation method allows assigning a mon-
etary value to time (however defined). On the other hand, the 
friction cost approach assumes that work-related productiv-
ity losses are expected to be mitigated due to the eventual 
replacement of absentees [32]. As such, this theory suggests 
that in the long run, the society will adapt and reach the origi-
nal production level as patients who leave the workforce are 
eventually replaced after an adaptation period. The costs 
associated with this short-term cycle are defined as friction 
costs. Some authors suggest that the friction cost method 
yields more accurate estimates compared to the human capi-
tal approach [8]. This is because friction costs do not over-
estimate the productivity losses by only considering the time 
it takes for society to replace the cases of absentees instead 
of assuming permanent vacancies. However, the friction cost 
approach usually neglects non-productive time (e.g. house-
hold production, leisure time) [33]. Although the human capi-
tal approach can be used to estimate non-market activity costs, 
the underlying assumptions need to be questioned to produce 
more nuanced and useful estimates. In particular, using a 
median wage to estimate lost wages due to cancer as opposed 
to actual wages could produce estimates that can be general-
ized across a broader population, which includes people who 
work at low-wage jobs. There are inherent assumptions about 
the value of time involved in the human capital approach, 
namely that the costs to individuals, families, and societies are 
higher if individuals earn higher wages; however, the burden 
is often highest for those with lower incomes. In other words, 
there are ethical implications to choices surrounding how to 
value indirect costs across a population.
We identified a trade-off between collecting primary data 
from patients and family members prospectively and using 
cross-sectional and longitudinal databases. Results from 
studies employing large administrative datasets are more 
easily generalizable to the overall population (if selected 
appropriately) and allow for the collection of individual-
level cost data for those who are represented therein. How-
ever, they have inherent limitations associated with the 
lack of quality controls and missing data issues. Prospec-
tive studies, on the other hand, allow for more precise data 
collection and, therefore, a more nuanced understanding of 
how cancer affects families across the care continuum. But 
these studies tend to be smaller in scale and may not address 
selection issues; their data collection may also be burden-
some to patients and families. As such, it is fundamental to 
acknowledge the different types of data sources to under-
stand the different ways in which the indirect cost burden 
can be reported. Although they provide an estimate of the 
indirect cost burden at different scales, both the micro (i.e. 
patient) and macro (i.e. societal) perspectives must be syn-
thesized and understood to adequately shape policy focused 
towards reducing this burden. This two-pronged approach 
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will provide a more comprehensive picture of the full indi-
rect cost burden that individuals and society incur.
4.1  Limitations
There were some limitations associated with the review. By 
limiting our search to studies published after 2006, we may 
have missed relevant papers and reports, grey literature, or non-
academic references that the previous reviews failed to cap-
ture. There were also limitations with the evidence identified. 
Although cost estimates can be useful in directing resources 
for programming, cancer care is highly variable according to 
clinical factors such as tumor site, stage of cancer care, and 
stage of diagnosis; population demographics; geographic loca-
tion; and coverage of oral chemotherapy and other types of 
medical and non-medical costs. Therefore, while aggregated 
cost estimates may help raise awareness of the overall cancer 
burden and allow for comparisons, greater efforts are needed 
to showcase the particular relevance to policy or programming 
to help address needs and barriers. Key clinical and popula-
tion variables to consider across all cost areas include cancer 
survival probability and curative intent (vs palliative care), 
stage of diagnosis and stage of life at diagnosis, the level of 
invasiveness of treatment and the consequences of treatment 
interventions, and variability in access by different populations 
to cancer treatment. Therefore, there is a need for stratified 
cost estimates by cancer site, patient groups, and the cancer 
care continuum. Furthermore, future work should focus on 
understanding the provision of support and access to resources 
across different settings, provinces, and workplaces, which are 
intended to help mitigate indirect costs.
5  Conclusion
This review makes an important contribution to the literature 
on the economic burden of cancer in Canada, in particular the 
indirect burden. Measuring and describing the indirect costs 
faced by cancer patients and their caregivers allows for a better 
understanding of the different types of productivity losses and 
time costs. Once the different categories of the indirect costs are 
understood, it is important to consider ways to integrate these 
inputs in economic evaluations to get a better picture of the actual 
burden of illness from different perspectives. For instance, when 
indirect costs to patients (e.g. missed days of work while hospital-
ized) are accounted for in economic evaluations, drug expenses 
could be considered to be cost effective. However, work-related 
productivity losses are not the only indirect costs that should be 
considered when conducting economic evaluations from a more 
comprehensive societal perspective. According to the guidelines 
for the economic evaluation of health technologies in Canada 
from the Canadian Agency for Drugs and Technologies in 
Health (CADTH), when conducting an evaluation from a soci-
etal perspective, all relevant costs to the patients, caregivers, and 
employers must be considered (e.g. patient out-of-pocket costs, 
patient time, lost productivity, home production costs, friction 
costs) [34]. This review suggests that the work productivity losses 
and the non-labor-market costs are considerable and should be 
considered in order to adequately measure the indirect burden 
from a societal perspective. These results will also help support 
a research agenda to fill the knowledge gaps with respect to direct 
and indirect costs of cancer across provinces and territories, and 
population sub-groups in Canada.
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